What is the efficacy of rivaroxaban (Xarelto) in the treatment of deep venous thrombosis (DVT)?

Updated: Jun 06, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print
Answer

Data from a pooled analysis of the EINSTEIN-DVT [7] and EINSTEIN-PE [8] trials suggested that rivaroxaban is as effective in preventing VTE recurrence as enoxaparin followed by a VKA and may be associated with less bleeding [9] ; in addition, the data suggested that there are no grounds for avoiding rivaroxaban use in high-risk groups (eg, fragile patients, cancer patients, and patients with a large clot).

Approximately 2.1% of patients treated with rivaroxaban experienced recurrent DVT or PE, compared with 1.8-3% treated with the enoxaparin and VKA combination. [7, 8]

Additionally, results from extended treatment demonstrated a reduced risk of recurrent DVT and PE. Approximately 1.3% in the rivaroxaban group experienced recurrent DVT or PE, compared with 7.1% in the placebo group. [119, 120]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!